Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-asan-ccgd-27-09-2019-00:22:21:191-59 - samples

ABSTRACT: 231 HCC exome sequencing with Sureselect 50Mb

PROVIDER: EGAD00001005361 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.

Ahn Sung-Min SM Jang Se Jin SJ Shim Ju Hyun JH Kim Deokhoon D Hong Seung-Mo SM Sung Chang Ohk CO Baek Daehyun D Haq Farhan F Ansari Adnan Ahmad AA Lee Sun Young SY Chun Sung-Min SM Choi Seongmin S Choi Hyun-Jeung HJ Kim Jongkyu J Kim Sukjun S Hwang Shin S Lee Young-Joo YJ Lee Jong-Eun JE Jung Wang-Rim WR Jang Hye Yoon HY Yang Eunho E Sung Wing-Kin WK Lee Nikki P NP Mao Mao M Lee Charles C Zucman-Rossi Jessica J Yu Eunsil E Lee Han Chu HC Kong Gu G

Hepatology (Baltimore, Md.) 20140922 6

<h4>Unlabelled</h4>Hepatic resection is the most curative treatment option for early-stage hepatocellular carcinoma, but is associated with a high recurrence rate, which exceeds 50% at 5 years after surgery. Understanding the genetic basis of hepatocellular carcinoma at surgically curable stages may enable the identification of new molecular biomarkers that accurately identify patients in need of additional early therapeutic interventions. Whole exome sequencing and copy number analysis was perf ...[more]

PMID: 24798001

Similar Datasets

Exome sequencing in classic Hairy cell leukaemia reveals widespread variation in acquired somatic mutations between individual tumours apart from the signature BRAF V(600)E lesion

Project description:Whole exome sequencing of 5 HCLc tumor-germline pairs. Genomic DNA from HCLc tumor cells and T-cells for germline was used. Whole exome enrichment was performed with either Agilent SureSelect (50Mb, samples S3G/T, S5G/T, S9G/T) or Roche Nimblegen (44.1Mb, samples S4G/T and S6G/T). The resulting exome libraries were sequenced on the Illumina HiSeq platform with paired-end 100bp reads to an average depth of 120-134x. Bam files were generated using NovoalignMPI (v3.0) to align the raw fastq files to the reference genome sequence (hg19) and picard tools (v1.34) to flag duplicate reads (optical or pcr), unmapped reads, reads mapping to more than one location, and reads failing vendor QC.

2016-02-01 | E-MTAB-4313 | biostudies-arrayexpress

Gene expression after treatment with anti-miR-191 or control

Project description:The goal of this experiment was to identify possible genes affected directly or indirectly by anti-miR-191. Hepatocellular carcinoma (HCC) is a fatal disease with currently very limited beneficial therapies. MicroRNAs (miRs), which are considered to be master regulators of gene expression, have significant influence on cellular pathways and phenotype, and are de-regulated in HCC, and hence are thought to be of great therapeutic potential as novel targets. We identified hsa-miR-191 as a potential target for HCC therapy. Inhibition of this miR causes decreased cell proliferation and induction of apoptosis in vitro as well as a significant reduction of tumor mass in vivo in an orthotopic liver xenograft model. This miR was also found to be up-regulated by a dioxin, a known liver carcinogen, and was found to be a key regulator of cancer related pathways. HCC cell line treated with anti-miR-191, and treated with negative control anti-miR. Treatment was done twice (duplicates) but in independent studies.

2011-07-01 | E-GEOD-22790 | biostudies-arrayexpress

miR expression after treatment with anti-miR-191 or control

Project description:The goal of this experiment was to study the effectivity of miR down regulation by using an anti-miR molecule. Hepatocellular carcinoma (HCC) is a fatal disease with currently very limited beneficial therapies. MicroRNAs (miRs), which are considered to be master regulators of gene expression, have significant influence on cellular pathways and phenotype, and are de-regulated in HCC, and hence are thought to be of great therapeutic potential as novel targets. We identified hsa-miR-191 as a potential target for HCC therapy. Inhibition of this miR causes decreased cell proliferation and induction of apoptosis in vitro as well as a significant reduction of tumor mass in vivo in an orthotopic liver xenograft model. This miR was also found to be up-regulated by a dioxin, a known liver carcinogen, and was found to be a key regulator of cancer related pathways. HCC cell line treated with anti-miR-191, and treated with negative control anti-miR. Although this experiment was done with dual channel, chanels are not compared, irrelevant samples were on the reciprocal channel. Sample data tables represent relevant, single channel data.

2011-07-01 | E-GEOD-22793 | biostudies-arrayexpress

LncRNA expression profiles of 59 tumorous liver tissues derived from patients with hepatocellular carcinoma (HCC)

2012-08-16 | GSE40144 | GEO

miR expression after treatment with anti-miR-191 or control

2011-07-01 | GSE22793 | GEO

Gene expression after treatment with anti-miR-191 or control

2011-07-01 | GSE22790 | GEO

LncRNA expression profiles of 59 tumorous liver tissues derived from patients with hepatocellular carcinoma (HCC)

Project description:Long noncoding RNAs (lncRNAs) are a class of non-coding RNAs longer than 200 nt that function in endogenous gene regulation and tumorigenesis. Hepatocellular carcinoma (HCC) is a heterogeneous disease with different treatment outcome. It is a challenge to develop a prognostic marker to identify HCC patients who are at greatest risk for recurrence or death. In this study, we try to screen lncRNAs whose expression levels are associated with recurrence or death of HCC patients through an extensive lncRNA profiling study on a cohort of 59 HCC patients. For these experiments, we used RNA extracted from 59 HCC tissues and 20 normal livers. Total RNAs from the 20 normal livers were pooled and used as a reference for all microarray experiments. For each microarray experiment, Cy5-labeled probes derived from the DNase-treated total RNA from each HCC sample was hybridized against Cy3-labeled probes derived from common reference on Arraystar Human LncRNA Microarray (Arraystar, Rockville, USA). LncRNAs whose expression was significantly associated with disease-specific survival and time to recurrence were selected based on microarray data. The univariate Cox proportional hazards model was used to assess the association of lncRNAs with survival. We computed a statistical significance level (P value) for two endpointsM-bM-^@M-^Tthe time to cancer-related death and time to recurrence, based on univariate Cox proportional hazards models in BRB-ArrayTools version 4.2.0.

2012-08-16 | E-GEOD-40144 | biostudies-arrayexpress

hsa-miR-191, a potential target for Hepatocellular carcinoma therapy

Project description:This SuperSeries is composed of the following subset Series: GSE22790: Gene expression after treatment with anti-miR-191 or control GSE22793: miR expression after treatment with anti-miR-191 or control GSE22909: Influence of TCDD onto HCC cell line Refer to individual Series

2011-07-01 | E-GEOD-22910 | biostudies-arrayexpress

EGAS00001000317-sc-20140326 - samples

Project description:The exome sequencing is performed using Agilent SureSelect 50Mb exome v3 and Hiseq 75bp paired reads with an mean sequencing coverage target of 50X.

| EGAD00001000799 | EGA